Within the pharmaceutical prescription sector, just like many other markets, maintaining competitive advantage has become increasingly difficult. In the healthcare arena, the period of time that a new chemical entity has on the market before a key competitor emerges has been significantly reduced. If a company has already developed an important market franchise in a given sector or disease area, it is essential that that company understands the potential threats it is likely to face in the future from new product entries and also to appreciate what, if anything, could be done to protect or enhance the product franchise in the light of market developments.
Get full access to this article
View all access options for this article.
References
1.
BlamiresC.. (1998) Pricing research in The ESOMAR Handbook of Market and Opinion Research, 4th edn, p. 767. ESOMAR.
2.
OrmeB.. (1996) Which conjoint method should I use?, in the Sawtooth Software Research Paper Series.
3.
PinnelJ.. (1994) Multistage conjoint methods to measure price sensitivity, paper presented at the Advanced Research Techniques Forum, Beaver Creek, Colorado, June.
4.
GreenP.E., & KriegerA.M. (1995) Attribute importance weights modification in assessing a brand's competitive potential, Marketing Science.
5.
PinnellJ., & OlsonP.. (1996) Using choicebased conjoint to assess brand strength and price sensitivity, in the Sawtooth Software Research Paper Series.
6.
WilliamsP., & KilroyD.. (2000) Calibrating price in ACA: the ACA price effect and how to manage it, in the Sawtooth Software Research Paper Series.
7.
WynerG.A. (1995) Tradeoff techniques and marketing issues, Marketing Research.
